Onchilles Reports Promising Results for Injectable Solid Tumor Treatment
By Dr. Zubair Khalid, DVM, MS, PhD ·
San Diego-based Onchilles Pharma has announced that its experimental therapeutic, N17350, demonstrated the ability to clear cancer lesions beyond the injection site when administered directly into a tumor. The company describes the molecule as one that "cancer hasn't seen before."
The vaccine-like treatment is delivered via injection into the tumor itself. According to the company, the candidate was able to eliminate cancer lesions that were distant from the site of the original injection. The results suggest that the therapy may trigger a systemic immune response against the cancer.
Onchilles believes N17350 represents a novel approach to treating solid tumors. The molecule is designed to be recognized by the immune system as foreign, potentially activating immune cells to attack cancer cells both at the injection site and elsewhere in the body.
Context for the life sciences: Intratumoral injections are an active area of cancer immunotherapy research. Most current immunotherapies, such as checkpoint inhibitors, work systemically but can cause widespread immune-related side effects. A treatment that generates a systemic anti-cancer response from a localized injection could offer a more targeted approach with potentially fewer side effects. This strategy also addresses a major challenge in oncology: treating metastatic disease, where tumors have spread beyond the primary site. If confirmed in larger studies, this approach could expand the toolkit for treating solid tumors that are difficult to reach or have already spread.
Source: original report